Publications

5808 Results

Impact of Sirtuin genes expression on first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)

Authors
P Mittal;Y Yang;K Ashouri;S Soni;F Battaglin;S Algaze;P Jayachandran;L Torres-Gonzalez;W Zhang;F Ou;A Venook;J Millstein;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

The prognostic impact of SLFN11 gene expression in metastatic colorectal cancer (mCRC) (Alliance)

Authors
H Arai;Y Yang;J Millstein;K Ashouri;F Ou;F Innocenti;F Battaglin;S Algaze;S Soni;W Zhang;A Venook;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Clinical and Molecular Characterization of FAP and SPP1 in Colorectal Cancer, CALGB (Alliance)/SWOG 80405 and Real-World Data

Authors
K Ashouri;Y Yang;J Millstein;J Xiu;S Soni;S Algaze;P Mittal;L Torres-Gonzalez;U Shah;A Shields;R Goldberg;E Lou;B Weinberg;J Marshall;S Mumenthaler;A Venook;S Finley;F Battaglin;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Expression of metabolic genes affects patients (pts) outcomes in metastatic colorectal cancer (mCRC): data from CALGB/SWOG 80405 (Alliance)

Authors
F Battaglin;J Millstein;Y Yang;K Ashouri;S Soni;S Algaze;P Mittal;L Torres-Gonzalez;P Jayachandran;U Shah;W Zhang;H Hochster;F Ou;A Venook;F Innocenti;S Finley;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Evaluation of CSF1R as a Prognostic and Predictive Biomarker in Colorectal Cancer

Authors
S Algaze;Y Yang;J Millstein;F Battaglin;S Soni;S Soni;P Mittal;K Ashouri;P Jayachandran;H Arai;L Torres Gonzalez;W Zhang;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

Lessons Learned from SWOG S1316: Optimizing Surgical Trial Design for Malignant Bowel Obstruction

Authors
M Farooq;N Amini;G Anderson;V Sun;G Deutsch;J Deneve;M Grant;R Krouse
Journal / Conference
Society for Surgical Oncology Annual Meeting (March 27-29, 2025, Tampa, FL)
Year
2025
Research Committee(s)
Palliative Care
Study Number(s)
S1316

Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT) - A randomized phase II study of Gemcitabine and NabPaclitaxel compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (NCT04233866)

Authors
E Dotan;P Catalano;L Lenchik;R Boutin;X Yao;J Ohr;K Lim;G Fisher;N Vijayvergia;S Chandana;A Kalyan;R Dunne;D Zhen;D Li;K Reiss;M Simon;J Berlin;L Waggoner;P O'Dwyer
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA)
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/EA2186

Efficacy and Safety of Cabozantinib for Advanced Gastrointestinal Neuroendocrine Tumors (NET) after Progression on Prior Therapy: A Subgroup Analysis of the Phase III CABINET Trial (Alliance A021602)

Authors
J Strosberg;T Zemla;S Geyer;M Knopp;S Behr;S Pulsipher;J Acoba;A Shergill;E Wolin;T Halfdanarson;B Konda;N Trikalinos;B Tawfik;N Raj;S Shaheen;N Vijayvergia;A Dasari;E O'Reilly;J Meyerhardt;J Chan
Journal / Conference
ASCO GI Cancers Symposium (January 23-25, 2025, San Francisco, CA), abstract 666
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021602

Approach to Treatment of Metastatic Hormone Sensitive Prostate (mHSPC) Cancer Among Cooperative Oncology Groups in North America

Authors
C Chalker;M Ong;R McKay;S Gulati;C Tangen;S Lerner;T Dorff;A Sokolova
Journal / Conference
ASCO GU Cancers Symposium (Feb 13-15, 2025, San Francisco, CA), poster
Year
2025
Research Committee(s)
Genitourinary

A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937- Updated Design

Authors
S Sadeghi;M Plets;P Lara;C Tangen;S Berg;J Brown;R Bangs;D Nakagawa;S Daneshmand;I Thompson;T Flaig;D Petrylak;S Lerner
Journal / Conference
ASCO GU Cancers Symposium (Feb 13-15, 2025, San Francisco, CA), Trials in Progress, TPS887
Year
2025
Research Committee(s)
Genitourinary
Study Number(s)
S1937